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Abstract
Upregulation of xCT, the inducible subunit of a membrane-bound amino acid transporter, replenishes intracellular
glutathione stores to maintain cell viability in an environment of oxidative stress. xCT also serves as a fusion-entry
receptor for the Kaposi’s sarcoma-associated herpesvirus (KSHV), the causative agento fK a p o s i ’ ss a r c o m a( K S ) .
Ongoing KSHV replication and infection of new cell targets is important for KS progression, but whether xCT
regulation within the tumor microenvironment plays a role in KS pathogenesis has not been determined. Using gene
transfer and whole virus infection experiments, we found that KSHV-encoded microRNAs (KSHV miRNAs) upregulate
xCT expression by macrophages and endothelial cells, largely through miR-K12-11 suppression of BACH-1—a
negative regulator of transcription recognizing antioxidant response elements within gene promoters. Correlative
functional studies reveal that upregulation of xCT by KSHV miRNAs increases cell permissiveness for KSHV infection
and protects infected cells from death induced by reactive nitrogen species (RNS). Interestingly, KSHV miRNAs
simultaneously upregulate macrophage secretion of RNS, and biochemical inhibition of RNS secretion by
macrophages significantly reduces their permissiveness for KSHV infection. The clinical relevance of these findings
is supported by our demonstration of increased xCT expression within more advanced human KS tumors containing a
larger number of KSHV-infected cells. Collectively, these data support a role for KSHV itself in promoting de novo
KSHV infection and the survival of KSHV-infected, RNS-secreting cells in the tumor microenvironment through the
induction of xCT.
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Introduction
Patients with immune deficiencies are at risk for life-
threatening illnesses caused by herpesviruses, including the
Kaposi’s sarcoma-associated herpesvirus (KSHV). Bone marrow
failure [1], lymphoproliferative syndromes [2,3], and sarcoma
[4] have all been etiologically linked to KSHV infection and
occur with greater frequency in the setting of immune
suppression related to HIV infection [5,6] or organ transplan-
tation [7,8]. The most commonly encountered clinical manifes-
tation of KSHV infection, Kaposi’s sarcoma (KS), represents one
of the most common tumors arising in the setting of HIV
infection, one of the most common transplant-associated tumors,
and a leading cause of morbidity and mortality [5–7]. Moreover,
KS is the most common tumor arising in the general population
in some geographic areas [9]. Despite the reduced incidence of
KS in the modern era of highly active antiretroviral therapy
(HAART) [10], KS is increasingly recognized in HIV-infected
patients with suppressed HIV viral loads and elevated CD4
+ T
cell counts [11,12]. Clinical responses to cytotoxic agents for
systemic KS vary widely in published trials, and these agents
incur many side effects which may exacerbate or add to those
already incurred by antiretroviral or immunosuppressive agents
[10,13]. Given these shortcomings of existing therapies, novel
targeted strategies are needed for the treatment or prevention of
KS.
PLoS Pathogens | www.plospathogens.org 1 January 2010 | Volume 6 | Issue 1 | e1000742Published data support a role for KSHV-encoded genes in KS
pathogenesis, including genes expressed primarily during lytic
replication that facilitate angiogenesis and endothelial cell
survival [14], and existing clinical data support this concept.
An elevated KSHV viral load in the peripheral circulation
predicts the onset and progression of both AIDS- and non-
AIDS-related KS, and intralesional KSHV viral load correlates
directly with tumor progression [15–17]. One retrospective
clinical study demonstrated that ganciclovir, a nucleoside analog
that inhibits viral DNA polymerase activity and reduces KSHV
replication [18], reduced the incidence of KS in patients
receiving organ transplants [19]. In addition, KS arising in the
setting of well-controlled HIV infection may be explained in part
by reduced KSHV-specific immunity despite general immune
recovery with HAART [20,21]. Together, these data suggest a
role for ongoing KSHV replication and infection of naı ¨ve target
cells in the progression of KS. Interestingly, neither KS lesional
spindle cells nor cultured endothelial cells infected by KSHV in
vitro efficiently maintain viral episomes when passed in culture
[22,23], suggesting the potential importance of additional
microenvironmental factors within KS tumors for facilitating
KSHV infection.
The amino acid membrane transport system xc
2 consists of
a conserved heavy chain, 4F2hc, and an inducible subunit,
xCT, that mediates amino acid exchange [24]. xc
2 exchanges
intracellular glutamate for extracellular cystine at the cell
membrane, and the latter is rapidly reduced in the intracellular
space to cysteine and incorporated into glutathione (GSH) and
other protein biosynthesis pathways [25]. This allows for
restoration of intracellular GSH stores and protection of xc
2-
expressing cells from oxidative stress and cell death [25]. xCT
expression is upregulated by physiological conditions that impact
intracellular GSH levels, such as hypoxia, inflammation, and
increased production of reactive species [25]. xCT was also
recently identified as a fusion-entry receptor for KSHV and may
mediate KSHV entry either in isolation or as part of a complex
with other receptors for the virus [26,27]. KSHV establishes
infection within multiple xCT-expressing cell types that have been
implicated in KS pathogenesis, including intralesional or circulat-
ing monocytes, intralesional macrophages, and endothelial cells
[26–29]. However, whether KSHV itself also regulates xCT
expression to promote viral infection of new cell targets or increase
the longevity of KSHV-infected cells in the local environment is
unknown.
miRNAs are small (19–23 nucleotides in length), non-coding
RNAs that bind target mRNAs, marking them for degradation or
post-transcriptional modification, and KSHV encodes 17 mature
miRNAs which are expressed within KSHV-infected cells and KS
lesions [30–33]. xCT expression is regulated through competitive
binding of positive and negative transcription factors to an
‘‘Antioxidant Response Element’’ (ARE) in the xCT promoter
[34,35], and existing data suggest that negative transcription
regulators of ARE may be targeted by KSHV miRNAs [36–40].
Therefore, using cell culture systems employing macrophages and
endothelial cells, we sought to determine whether KSHV miRNAs
regulate the expression of xCT, and if so, whether this infuences
cell permissiveness for KSHV infection and protection of infected
cells from oxidative stress.
Results
xCT is a principal determinant of macrophage
permissiveness for KSHV infection
To first determine whether xCT expression correlates with
macrophage susceptibility to KSHV infection, we utilized a
BALB/c-derived murine macrophage cell line, 264.7 cells
(‘‘RAW’’ cells). We chose RAW cells given the recent demonstra-
tion of KSHV infection of murine macrophages in vivo [41], the
identity (89%) and similarity (93%) of the murine xCT protein to
its human counterpart [25], and the utility of these cells for gene
transfer studies. xCT expression is induced indirectly by substrates
that compete for cystine uptake by xCT, like monosodium
glutamate (Msg) [42] and sulfasalazine (Sul) [43]. We found that
Msg or Sul significantly increased the number of RAW cells
expressing the KSHV latency-associated nuclear antigen (LANA)
following their incubation with purified KSHV (Fig. 1A–E). This
increase in the number of infected cells was reflected in an increase
in viral episome copies for cells from Msg- and Sul-treated cultures
(Fig. 1F), although IFA suggested that the number of episomes
(LANA dots) per cell was unchanged (Fig. 1A–D). Msg and Sul
also increased xCT transcript expression by RAW cells (Fig. 1G),
and direct targeting of xCT with siRNA significantly reduced the
number of LANA-positive cells following RAW cell incubation
with KSHV (Fig. 1H and I). These data confirm the role of xCT as
a principal determinant of RAW cell susceptibility to KSHV
infection.
KSHV miRNAs regulate xCT expression and macrophage
permissiveness for KSHV infection
To explore whether KSHV miRNAs regulate xCT expression,
we co-transfected RAW cells with a construct encoding 10 of the
17 mature KSHV miRNAs described elsewhere [44]. Using semi-
quantitative RT-PCR, we first confirmed upregulation of xCT
with the collective expression of KSHV miRNAs encoded in the
construct (Fig. 2A). Using a KSHV miRNA target prediction
algorithm validated previously [36], we identified KSHV miRNA
binding sites within 3’UTR of several murine genes associated
with the regulation of xCT. The majority of binding sites were
identified for 3 KSHV miRNAs: miR-K12-1, miR-K12-9, and
miR-K12-11 (data not shown). To first determine whether these
miRNAs were expressed within KSHV miRNA transfectants, we
co-transfected cells with KSHV miRNAs and pGL3 luciferase
Author Summary
Herpesviruses are the most common etiologic agents of
cancer in patients with suppressed immune function, and
the Kaposi’s sarcoma-associated herpesvirus (KSHV) is one
of the most common causes of cancer in this setting. KSHV
infection of new cell targets is critical for tumor
progression, and a better understanding of how viral
receptors on the surface of cells are regulated in the tumor
microenvironment may lead to new therapies. KSHV
encodes unique RNAs called microRNAs (KSHV miRNAs)
that regulate a variety of cell functions. In this study, we
show that KSHV miRNAs increase the susceptibility of cells
to KSHV infection and protect infected cells from death
induced by cancer-promoting reactive nitrogen species
(RNS). They accomplish this in large part by increasing cell
surface expression of a transport protein subunit called
xCT. We also show that KSHV miRNAs increase secretion of
RNS by infected cells, and that blocking RNS secretion
reduces the ability of KSHV to infect cells. Therefore, by
regulating xCT and RNS, we find KSHV is able to ‘‘fine-
tune’’ cell function in order to maintain a stable population
of infected cells which secrete cancer-promoting factors in
the local environment. This work has important implica-
tions for developing new therapies to target xCT and
reduce survival of KSHV-infected tumor cells.
Upregulation of xCT by KSHV-Encoded MicroRNAs
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individual miRNAs (upon binding of pGL3 complimentary
sequences to mature miRNAs, luciferase expression by pGL3 is
repressed as shown elsewhere) [44]. This confirmed expression of
miR-K12-1, miR-K12-9, and miR-K12-11 in these cells (Fig. 2B).
Next, using qRT-PCR, we found that miR-K12-1, miR-K12-9,
and miR-K12-11 are responsible for the upregulation of xCT in
KSHV miRNA transfectants since targeting these 3 miRNAs with
specific 2’OMe RNA antagomirs entirely suppressed this effect
(Fig. 2C). Parallel experiments revealed that KSHV miRNAs
increase intracellular KSHV viral load and viral transcript
expression within macrophages following their incubation with
KSHV (Fig. 3A and B). Once again, this effect was entirely
suppressed by targeting miR-K12-1, miR-K12-9, and miR-K12-
11 (Fig. 3A and B). In addition, we found that siRNA targeting of
xCT significantly suppressed the KSHV miRNA-mediated
increase in macrophage susceptibility to KSHV infection
(Fig. 3C).
KSHV miR-K12-11 suppresses BACH-1 to induce xCT
expression and cell permissiveness for KSHV infection in
macrophages and endothelial cells
Our bioinformatics analyses revealed putative binding sites for
miR-K12-11 within the 3’UTR of the murine BACH-1 gene
(Fig. 4A). We subsequently confirmed KSHV miRNA suppression
of BACH-1 within RAW cells, an effect largely reversed through
direct targeting of KSHV miR-K12-11 (Fig. 4B). In addition,
direct siRNA targeting of BACH-1 significantly increased basal
levels of xCT expression in these cells (Fig. 4C–E) as well as
macrophage permissiveness to KSHV infection (Fig. 4F), although
to a lesser degree than the collective expression of miR-K12-1,
miR-K12-9, and miR-K12-11 (Fig. 3).
Published data have confirmed direct targeting of BACH-1 by
miR-K12-11 in human cells [36]. To validate our observations
and to determine their broader significance for human cells with
known relevance to KS pathogenesis, we repeated our experi-
ments using primary human umbilical vein endothelial cells
Figure 1. xCT mediates KSHV infection of macrophages. (A–D) 264.7 (‘‘RAW’’) cells were first incubated with Monosodium glutamate (Msg),
Sulfasalazine (Sul) or vehicle control (DMSO) for 12 h followed by purified KSHV (K). 16 h later, IFA employing anti-LANA monoclonal antibodies and
secondary antibodies conjugated to Texas Red were performed to identify expression of LANA signified by the typical punctate intranuclear
expression pattern. Nuclei were identified using DAPI (blue). Some cells were incubated with UV-inactivated virus (UV-K) for negative controls.
Representative images from one of three independent experiments are shown. (E) Relative infection rate was determined for groups in A–D as
outlined in Methods. (F) qPCR was used to determine relative intracellular KSHV DNA content normalized to the vehicle control group (relative viral
copies) as explained in Methods. (G) qRT-PCR was used to determine relative xCT transcript expression. (H) qRT-PCR was used to determine xCT
transcript expression relative to control cells for cells transfected with either control (n) or xCT-specific siRNA. (I) Relative infection rates were
calculated for groups in (H) using LANA IFA. For all assays, error bars represent the S.E.M. for three independent experiments. * *=p,0.01.
doi:10.1371/journal.ppat.1000742.g001
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transfection significantly increased xCT transcript expression
and, based on IFA, KSHV episome copy number per cell following
subsequent de novo infection (Fig. 5A–J). In contrast to what was
observed for RAW cells, IFA indicated that the total number of
infected HUVEC remained unchanged with these interventions
(Fig. S1). In addition, either direct suppression of xCT by siRNA
or concurrent inhibition of miR-K12-11 reduced xCT expression
and intracellular viral load in KSHV miRNA transfectants
(Fig. 5H–J). Collective expression of KSHV miRNAs also reduced
BACH-1 expression in HUVEC, an effect suppressed with
concurrent inhibition of miR-K12-11 (Fig. 5K).
KSHV miRNAs upregulate macrophage secretion of
reactive nitrogen species (RNS) and protect macrophages
from RNS-induced cell death
xCT restoration of intracellular glutathione and increased
scavenging of free radicals reduces cell death resulting from
nitration of proteins, lipids, and nucleic acids by RNS [25,45,46].
Because we observed increased xCT expression induced by
KSHV miRNAs, we hypothesized that KSHV may also increase
RNS secretion by macrophages and that xCT upregulation
would serve as an auto-protective mechanism in this environ-
ment. Using a standard Greiss reaction assay for quantifying
nitrite in culture supernatants as a surrogate measure of RNS
secretion, we found that KSHV infection of RAW cells induced a
,20-fold increase in RNS secretion and that the majority of this
effect was mediated through the collective expression of miR-
K12-1, miR-K12-9, and miR-K12-11 (Fig. 6A). A similar pattern
was observed following overexpression of KSHV miRNAs
( F i g .6 Ba n dC ) .N o n - s p e c i f i cT L Ra c t i v a t i o n ,a sm i g h tb e
initiated by mature miRNAs or their precursors, is capable of
inducing RNS production [47,48]. However, specific inhibitors
of MyD88-independent and -dependent toll-like receptor (TLR)
pathways failed to reduce induction of RNS secretion by KSHV
miRNAs, suggesting that this effect is not mediated through TLR
activation (Fig. S2).
To determine whether upregulation of xCT by KSHV
miRNAs offers a protective mechanism for macrophages in an
Figure 2. KSHV miRNAs upregulate xCT expression by macrophages. (A) RT-PCR was used to determine expression of xCT transcripts in
RAW cells transfected with either control (pc) or miRNA-expressing vectors (pc-miRNA). b-actin was used as a loading control. (B) RAW cells were co-
transfected with miRNA luciferase reporter constructs (pGL3-miX where X=complimentary sequence for the individual KSHV miRNAs noted) and
either control or miRNA-expressing vectors. 48 h later, luciferase expression was determined for miRNA transfectants relative to controls (RLU). (C)
Cells were transfected with control or miRNA-expressing vectors with or without 2’OMe RNA antagomirs targeting miR-K12-1, miR-K12-9, and miR-
K12-11 (mi1/9/11). 48 h following subsequent incubation with KSHV (K), qRT-PCR was used to determine relative xCT transcript expression. For all
assays, error bars represent the S.E.M. for three independent experiments. * *=p,0.01.
doi:10.1371/journal.ppat.1000742.g002
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the nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine
(SNAP) [49] increased RNS concentrations within RAW cell
culture supernatants and induced cell death in a dose-dependent
manner (Fig. 7A and B). Subsequently, we found that either
KSHV infection or overexpression of KSHV miRNAs signifi-
cantly increased macrophage resistance to SNAP-induced cell
death. Moreover, siRNA experiments confirmed that this effect
was mediated primarily through the upregulation of xCT
(Figs. 7C and D).
RNS facilitate KSHV infection of macrophages
RNS are expressed within KS lesions [50], but whether RNS
themselves influence de novo KSHV infection is unknown. To
reduce macrophage secretion of RNS, we incubated RAW cells
with L-N
6-monomethyl-arginine (L-NMMA), an inhibitor of all
forms of nitric oxide synthase (NOS) [51] that induces no
discernable toxicity for RAW cells over a wide range of
concentrations (Fig. S3). Interestingly, L-NMMA significantly
reduced secretion of RNS initiated by KSHV miRNAs and
reduced de novo KSHV infection of macrophages in a dose-
dependent manner (Fig. 8), suggesting a role for NOS and RNS in
facilitating de novo KSHV infection.
xCT expression is increased within more advanced KS
lesions
KSHV miRNAs are expressed within KS lesions [30–32]
but to our knowledge, expression of xCT within KS tissue has
never been demonstrated. To address this, we used immuno-
histochemistry to quantify xCT expression within KS skin
lesions representing the full spectrum of histopathologic
progression of KS. We found that stage I tumors (patches)
and stage II tumors (plaques) exhibited either no or minimally
discernable xCT expression, respectively (Fig. 9). In contrast,
stage III tumors (nodules) exhibited easily discernable mem-
brane expression of xCT by the majority of cells in these
lesions, including nearly all spindle-shaped cells (Fig. 9).
Moreover, we confirmed that stage III tumors exhibited
significantly more LANA
+ cells than stage I lesions (Fig. S4)
in agreement with published data [52,53] as well as our
Figure 3. KSHV miRNA upregulation of xCT increases macrophage susceptibility to KSHV infection. (A) RAW cells were transfected
with control or miRNA-expressing vectors then incubated with purified KSHV (K). LANA IFA were performed 16 h later, and relative infection rates
were determined as outlined in Methods. (B) qPCR was used to determine relative intracellular KSHV DNA content for groups in A. (C) Cells were co-
transfected with control or miRNA-expressing vectors and either control (n) or xCT-specific siRNA then incubated with purified KSHV. 16 h later,
LANA IFA were used to determine relative infection rates. For all assays, error bars represent the S.E.M. for three independent experiments.
**=p ,0.01.
doi:10.1371/journal.ppat.1000742.g003
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expression in our in vitro experiments.
Discussion
In this study, we found that KSHV-encoded miR-K12-11
upregulates the expression of xCT in macrophages and endothelial
cells, in part through suppression of a negative regulator of gene
transcription, BACH-1. We also found that KSHV miRNAs
induce macrophage secretion of RNS and protect these cells from
RNS-induced cell death through the upregulation of xCT.
Moreover, reducing NOS activity and RNS secretion by
macrophages reduces their permissiveness for KSHV. Finally,
we found that cells within more advanced human KS tumors
express more xCT than cells from early-stage lesions. We
hypothesize, therefore, that KSHV miRNAs facilitate KS
pathogenesis through cooperative mechanisms that regulate xCT
and RNS secretion to promote ongoing de novo infection and
survival of infected cells in the tumor microenvironment.
Implications of the regulation of BACH-1, xCT expression,
and cell susceptibility to KSHV infection by KSHV miRNAs
xCT expression is differentially regulated during oxidative stress
through transcription factor binding to the cis-acting ARE in its
promoter [34,35]. Transcription factors that bind to the ARE
include a positive regulator known as Nuclear factor erythroid 2-
related factor-2 (Nrf-2) [35] and negative regulators, including
BACH-1 and c-Maf, which competitively reduce Nrf-2 binding to
the ARE thereby repressing ARE-mediated gene expression
[37,38]. KSHV miRNAs are expressed within KSHV-infected
cells and KS lesions [30–32], and existing data suggest that both
BACH-1 and c-Maf are targeted by KSHV miRNAs [36,39,40].
More specifically, KSHV miR-K12-11, an ortholog of cellular
miR-155, targets and reduces expression of BACH-1 [36]. miR-
155 downregulates c-Maf expression by T cells [40], and KSHV
miRNAs downregulate c-Maf expression in endothelial cells [39].
Therefore, we hypothesized that miR-K12-11, in cooperation with
other KSHV miRNAs, regulates xCT expression.
Figure 4. KSHV miRNAs upregulate xCT expression through repression of BACH-1. (A) Potential KSHV miRNA binding sites were identified
within the 3’UTR of murine BACH-1 using an ad-hoc scanning program as described in Methods. miR-K12-11 nucleotides with matching base pairs
depicted in capital letters bind within positions 2318–2339 and 2530–2551. (B) RAW cells were transfected with 1 mg control or miRNA-expressing
vectors with or without 300 pmol of 2’OMe RNA antagomirs targeting miR-K12-11. 48 h later, BACH-1 expression was quantified by Western blot. b-
Actin was used for loading controls. Numbers represent immunoreactivity relative to control transfectants as quantified using Image-J software. (C–
D) RT-PCR (C) and qRT-PCR (D) were used to quantify transcripts for BACH-1 (C) and xCT (C and D), respectively, in controls cells or cells transfected
with either control (n) or BACH-1-specific siRNA. (E) Western blots were used to quantify BACH-1 protein expression in siRNA-transfected cells for
groups in (C). Immunoreactivity was quantified as in (B). (F) Cells were transfected with control or BACH-1 siRNA as above and subsequently
incubated with KSHV. Relative infection rates were determined 12 h later using LANA IFA. Error bars represent the S.E.M. for three independent
experiments. * *=p,0.01.
doi:10.1371/journal.ppat.1000742.g004
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induced xCT expression in both macrophages and endothelial
cells, although additional experiments using site-directed muta-
genesis are needed to confirm direct interactions between BACH-
1 and the xCT ARE in murine cells. Further validating our
findings, we found that BACH-1 targeting by siRNA increased
macrophage permissiveness for infection by approximately 70%
(Fig. 4F), although overexpression of multiple miRNAs increased
permissiveness by approximately 250% (Fig. 3E). Differences in
transfection efficiency for siRNA and the KSHV miRNA
constructs could be partially responsible for this discrepancy, but
we hypothesize that it is due in part to the effect of multiple KSHV
miRNAs, including miR-K12-1 and miR-K12-9, and the
cooperative targeting of multiple genes. Our initial screen for
KSHV miRNA binding sites within murine and human genes
known to regulate xCT expression and RNS secretion revealed
multiple binding sites for miR-K12-1, miR-K12-9 and miR-K12-
11 (data not shown). These analyses also revealed binding sites for
miR-K12-4, although not miR-K12-1 or miR-K12-9, within both
murine and human BACH-1 3’UTR sequences (not shown),
although we have not yet confirmed the functional impact of miR-
K12-4 expression on BACH-1 or xCT expression. Additional
studies are needed to confirm direct targeting of BACH-1 or other
genes by these KSHV miRNAs and to characterize the functional
impact of this targeting for expression of xCT and other ARE-
containing genes regulated by BACH-1, including those involved
in the generation of RNS (see below).
To our knowledge, these data are the first to suggest a role for a
herpesvirus in the autocrine upregulation of its own receptor,
although whether increased cell permissiveness for KSHV entry
following initial infection and miRNA expression is ‘‘accidental’’
or ‘‘purposeful’’ in the context of KSHV-host evolution remains
debatable. In addition to promoting cell survival (see below),
autocrine upregulation of xCT may provide evolutionary
advantages for the virus achieved through an increase in
intracellular viral load that were not addressed by our studies.
Figure 5. miR-K12-11 suppresses BACH-1 expression and increases endothelial cell susceptibility to KSHV through upregulation of
xCT. (A–G) HUVEC were incubated with vehicle control (DMSO), Msg, or Sul for 12 h followed by purified KSHV (K) using an MOI,0.5–1. 16 h later,
LANA IFA were performed as previously described. (A–D) Representative images from one of three independent experiments are shown. (H–K)
HUVEC were transfected with control or miRNA-expressing vectors along with a 2’OMe RNA antagomir for miR-K12-11 or either control (n) or xCT-
specific siRNA. (E,H) Relative LANA expression was determined as described in Methods. (F,I) qRT-PCR was used to determine relative xCT transcript
expression. (G,J) qPCR was used to determine relative intracellular KSHV DNA content normalized to controls. (K) Western blots were used to identify
BACH-1 protein expression and immunoreactivity quantified as previously described. For all assays, error bars represent the S.E.M. for three
independent experiments. *=p,0.05, * *=p,0.01 (For Fig. H–J, comparisons are relative to either pc-miRNA or pc-miRNA+K).
doi:10.1371/journal.ppat.1000742.g005
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significant proportion of KSHV-infected tumor cells, including
those within KS lesions, contain multiple viral clones [54–56].
Another study showed that the downregulation of MHC Class I
(MHC-I) in KSHV-infected cells is directly proportional to the
level of expression of the KSHV modulator of immune recognition
2 (MIR2) and intracellular KSHV episome copy number [57],
implying that increasing intracellular viral copies may promote
reduced KSHV epitope presentation to CD8
+ T cells as a
mechanism for immune evasion. Our IFA indicated that for RAW
cells, miRNA upregulation of xCT increased the permissiveness of
uninfected cells for KSHV, although not viral episome copies
within individual cells. In contrast, miRNA upregulation of xCT
increased HUVEC viral episome copies per cell following
subsequent infection, although not the total number of infected
cells. Our studies did not directly address whether the observed
increase in episome copies per cell for HUVEC is the result of
intracellular episome replication or ‘‘superinfection’’ with exoge-
nous virions. Experiments utilizing limiting dilution PCR [58] or
single cell imaging techniques [41,59] could be used to confirm
whether intracellular KSHV viral load and miRNA expression
correlate with xCT expression on a single cell level and to address
the possibility that KSHV miRNA upregulation of xCT increases
cell permissiveness for subsequent virion entry. It is interesting to
speculate whether autocrine regulation of surface receptors by
KSHV miRNAs differs depending on the cell type, and whether
soluble factors released by infected cells differentially influence
xCT expression for different cell types.
Implications of the regulation of RNS secretion, xCT
expression, and survival of KSHV-infected cells by KSHV
miRNAs
Our data indicate a role for KSHV miRNAs in the induction of
RNS secretion and the protection of cells from RNS-induced cell
death through the upregulation of xCT. Of additional relevance,
we found that L-NMMA, an inhibitor of NOS, reduced KSHV
miRNA-induced secretion of RNS and de novo KSHV infection.
Additional studies are currently underway to elucidate the
Figure 6. KSHV miRNAs induce reactive nitrogen species (RNS) secretion by macrophages. (A) RAW cells were transfected with 2’OMe
RNA antagomirs targeting miR-K12-1, miR-K12-9, and miR-K12-11 or all three together (mi1/9/11). Cells were subsequently incubated with purified
KSHV (K) and nitrite quantified within culture supernatants as described in Methods. (B) Cells were transfected with control or miRNA-expressing
vectors and nitrite quantified within culture supernatants at the times indicated. (C) Cells were co-transfected with either control or miRNA-
expression constructs without (mock) or with specific 2’OMe RNA antagomirs. As an additional control, some cells were transfected with an
antagomir targeting miR-K12-12 which is not expressed by the miRNA-expressing construct. For all assays, error bars represent the S.E.M. for three
independent experiments. *=p,0.05, * *=p,0.01.
doi:10.1371/journal.ppat.1000742.g006
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extracellular or intracellular proteins, RNS activate Nrf-2
[34,35,60] and, therefore, may upregulate xCT expression
through both autocrine and paracrine mechanisms. It is also
conceivable that miR-K12-11 downregulation of BACH-1 in-
creases expression of other ARE-containing genes involved in the
induction of RNS or the protection of cells from oxidative stress,
including heme oxygenase-1 (HO-1) [34,35]. Interestingly, HO-1
is expressed within KS lesions, and KSHV infection of endothelial
cells induces activation of HO-1 [61]. It is probable that RNS
secretion and downstream consequences are mediated through the
collective targeting of multiple genes by KSHV miRNAs, and that
this may occur within a variety of KSHV-infected cells with the
capacity to secrete RNS, including endothelial cells and dendritic
cells [25]. Characterization of miRNA regulation of RNS for a
broader array of cell types relevant to KS pathogenesis is
underway. Furthermore, our studies do not address whether
KSHV miRNAs regulate secretion of reactive oxygen species
(ROS) by infected cells, and it is conceivable that ROS play a role
in the paracrine regulation of xCT or other events pertaining
to KSHV infection. Studies are ongoing in our laboratory to
define the relative importance of specific reactive species in the
regulation of xCT expression and KSHV dissemination in the
microenvironment.
Multiple studies implicate RNS in KS pathogenesis [46,50,62–
66]. RNS and NOS are expressed within KS lesions [50,62], and
RNS induce endothelial cell migration, proliferation and angio-
genesis [46] as well as T cell apoptosis [63]. Moreover, existing
data support a role for KSHV in the regulation of superoxide
dismutase (SOD) in the KS microenvironment [50,67], and
cytokines associated with KS pathogenesis have been implicated in
the activation of RNS secretion by macrophages [64,65].
Interestingly, a recent publication demonstrated that Rac1
transgenic mice overexpressing NADPH-oxidase-dependent reac-
tive species developed KS-like lesions and that systemic admin-
istration of the antioxidant N-acetylcysteine reduced KS formation
in this model [66]. Preliminary experiments performed in our
laboratory have revealed that inhibition of NADPH-oxidase using
diphenylene iodonium (DPI) also reduces KSHV miRNA-induced
RNS secretion and infection of naı ¨ve cells (data not shown). In
addition, at least one study has implicated cellular miRNAs in the
regulation of Rac1 [68]. Therefore, our findings have important
implications for paracrine regulation of cellular events pertaining
to KS pathogenesis, and systemic inhibition of RNS may interfere
Figure 7. KSHV miRNAs enhance macrophage survival in an environment of oxidative stress through the upregulation of xCT. (A)
RAW cells were treated with the indicated concentrations of SNAP or vehicle control for 12 h prior to nitrite quantification within culture
supernatants. (B) Relative cell viability was determined for groups in (A) as described in Methods. (C) Cells were transfected with either control (n) or
xCT-specific (x) siRNA and incubated with UV-K (KSHV2) or KSHV (KSHV+) 48 h later. (D) Cells were co-transfected with xCT siRNA and either control
or miRNA-expressing vectors for 48 h, then incubated for an additional 12 h with SNAP prior to viability determinations. For all assays, error bars
represent the S.E.M. for three independent experiments. *=p,0.05, * *=p,0.01.
doi:10.1371/journal.ppat.1000742.g007
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angiogenesis.
Clinical implications of xCT expression within KS lesions
We have demonstrated that xCT is expressed to a greater extent
within more advanced KS lesions containing a greater number of
KSHV-infected cells. To our knowledge, these are the first data to
demonstrate xCT expression in clinical samples from KSHV-
infected patients and are consistent with published data docu-
menting higher KSHV intratumoral viral loads within more
advanced KS lesions [52,53]. Importantly, they also support our
hypothesis that KSHV upregulation of xCT facilitates expansion
of the KSHV reservoir in the microenvironment and KS
progression. Moreover, our observation that spindle-shaped cells
within stage III tumors express xCT is consistent with our data
revealing upregulation of xCT and KSHV permissiveness for
endothelial cells in vitro by KSHV miRNAs. Additional studies are
needed to confirm whether KSHV miRNAs, BACH-1 and other
putative xCT regulatory factors are differentially expressed during
different stages of KS progression. Future translational studies may
also shed light on whether quantifying xCT in clinical samples
provides additional prognostic information for patients at risk for
KS, and whether targeting xCT or its regulatory pathways will




BCBL-1 cells were grown in RPMI 1640 media (Gibco)
supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES
(pH 7.5), 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM
L-glutamine, 0.05 mM b-mercaptoethanol, and 0.02% (wt/vol)
sodium bicarbonate. Murine macrophages, RAW 264.7 cells
(RAW cells), were obtained from American Type Culture
Collection (ATCC) and grown in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco) supplemented with 10% FBS. HeLa
cells were grown in DMEM supplemented with 10% FBS, 100 U/
mL penicillin and 100 mg/mL streptomycin. Human umbilical
vein endothelial cells (HUVEC) were grown in DMEM/F-12 50/
50 medium (Cellgro) supplemented with 5% FBS and 0.001 mg/
mL Puromycin (Sigma).
Antibodies and reagents
Antibodies recognizing BACH-1 (H-130) and b-Actin were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and
Figure 8. RNS inhibition reduces macrophage susceptibility to KSHV infection. (A) RAW cells were first transfected with 1 mg of either
control or miRNA-expressing vectors then incubated with L-NMMA for 12 h prior to nitrite quantification in culture supernatants. (B) Cells were
incubated with L-NMMA for 12 h prior to their incubation with purified KSHV (K) for 2 h. Following an additional 12 h, LANA IFA were performed and
relative infection rates determined as described in Methods. (C) qPCR was used to determine relative intracellular KSHV DNA content for KSHV-
infected cells pre-treated with either vehicle or 0.5mM L-NMMA. In all assays, error bars represent the S.E.M. for three independent experiments.
*=p,0.05, * *=p,0.01.
doi:10.1371/journal.ppat.1000742.g008
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purchased from Sigma (St. Louis, MO). SNAP was purchased
from Invitrogen (Eugene, Oregon).
Transfection assays
A 2.8 Kbp construct encoding 10 individual KSHV micro-
RNAs (pcDNA-miRNA, containing miR-K12-1/2/3/4/5/6/7/
8/9/11), and luciferase reporter constructs encoding complimen-
tary sequences for individual miRNA (pGL3-miRNA sensors),
have been validated previously in transfection assays for expression
of KSHV miRNAs [44]. These constructs were used to transiently
transfect RAW cells and HUVEC. For inhibition of mature
miRNAs, 2’OMe RNA antagomirs were designed and purchased
from Dharmacon (Chicago, IL) as previously described [44].
BACH-1, xCT, and non-target (control) siRNAs (ON-TARGET
plus SMART pool) were also purchased from Dharmacon. Cells
were transfected with 1 mg pcDNA-miRNA, 0.5 mg pGL3-
miRNA sensors, 300 pmol 2’OMe RNA antagomirs, siRNAs,
and/or 1 mg pcDNA for negative controls in 12-well plates using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and/or Dharma-
FECT Transfection Reagent (Dharmacon, Chicago, IL) for 48 h
prior to their incubation with KSHV. For miRNA inhibitor
assays, control cells were transfected with a 2’OMe RNA
antagomir targeting miR-K12-12, a KSHV miRNA not encoded
by the pcDNA-miRNA construct. For luciferase expression assays,
cells were incubated with 100 mL lysis buffer (Promega, Madison,
WI), and luciferase activity determined within lysates using a
Berthold FB12 luminometer (Titertek, Huntsville, AL). Light units
were normalized to total protein levels for each sample using the
BCA protein assay kit according to the manufacturer’s instructions
(Pierce, Rockford, IL). Transfection efficiency was assessed
through co-transfection of a lacZ reporter construct kindly
provided by Dr. Yusuf Hannun (Medical University of South
Carolina, Charleston, SC), and b-galactosidase activity deter-
mined using a commercially available b-galactosidase enzyme
assay system according to the manufacturer’s instructions
(Promega, Madison, WI). 3 independent transfections were
performed for each experiment, and all samples were analyzed
in triplicate for each transfection.
Nitrite quantification
Nitrite concentrations within culture supernatants were deter-
mined using the Griess Reagent System (Promega, Madison, WI)
according to the manufacturer’s instructions.
Immunoblotting
Cells were lysed in buffer containing 20 mM Tris (pH 7.5),
150 mM NaCl, 1% NP40, 1 mM EDTA, 5 mM NaF and 5 mM
Na3VO4.3 0mg of total cell lysate was resolved by SDS–10%
PAGE and transferred to nitrocellulose membranes prior to
incubation with antibodies for proteins of interest as well as b-
Actin for loading controls. Immunoreactive bands were developed
by enhanced chemiluminescence reaction (Perkin-Elmer), visual-
ized by autoradiography, and quantified using Image-J software.
Bioinformatics analysis
The 3’UTR sequences of BACH-1 and other RNS-associated
genes were obtained from Ensembl (http://www.ensembl.org).
3’UTRs were analyzed to extract all potential KSHV miRNA
binding sites using an ad-hoc scanning program specifically
developed to assess 3’UTR KSHV miRNA seed sequence
matching, as validated previously [36].
KSHV purification and infection
BCBL-1 cells were incubated with 0.6 mM valproic acid for 4–6
days, and KSHV was purified from culture supernatants by
Figure 9. xCT expression within KS lesions correlates with tumor stage. KS diagnosis and histopathologic staging were independently
confirmed by a dermatopathologist using hematoxylin and eosin (H & E). Tumors were then processed for immunohistochemistry as described in
Methods using either pre-immune sera (control) or xCT anti-sera. xCT expression is revealed by dark brown membrane-associated staining in contrast
to blue nuclear staining. Representative images from all stages (I=patch, II=plaque, III=nodule) are shown, including two different stage III tumors
(A and B). All images are shown at original magnification 620 or 60.
doi:10.1371/journal.ppat.1000742.g009
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resuspended in 1/100 the original volume in the appropriate
culture media, and aliquots were frozen at 280uC. Target cells
were incubated with concentrated virus in the presence of 8 mg/
mL polybrene (Sigma-Aldrich) for 2 h at 37uC. Inactivated KSHV
used for negative controls was prepared by incubating viral stocks
with ultraviolet (UV) light (1200 J/cm
2) for 109 in a CL-1000
Ultraviolet Crosslinker (UVP). The concentration of infectious
viral particles used in each experiment (multiplicity of infection
[MOI]) was calculated as previously described [57,69].
Immunofluorescence assays and determination of
relative infection rates
1610
4 RAW cells or HUVEC were seeded per well in eight-
well chamber slides (Thermo Fisher, Rochester, NY) and
incubated with viral stocks (MOI,10 for RAW cells,
MOI,0.1–1 for HUVEC) in the presence of 8 mg/mL polybrene
(Sigma-Aldrich) for 2 h at 37uC. 16 h later, cells were fixed and
permeabilized following incubation with 1:1 methanol-acetone for
109 at 220uC. To reduce non-specific staining, slides were
incubated in blocking reagent (10% normal goat serum, 3%
bovine serum albumin, and 1% glycine) for 309. To identify
expression of the latency-associated nuclear antigen (LANA) of
KSHV, cells were subsequently incubated with 1:1000 dilution of
an anti-LANA rat monoclonal antibody (ABI) for 1 h, followed by
a goat anti-rat secondary antibody (1:100) conjugated to Texas
Red (Invitrogen) for 1 h at 25uC. Nuclei were subsequently
counterstained with 0.5 mg/mL 49,6-diamidino-2-phenylindole
(DAPI; Sigma-Aldrich) in 180 mM Tris-HCl (pH 7.5). Slides
were examined at 606 magnification using a Nikon TE2000-E
fluorescence microscope. Infection rates were determined follow-
ing examination of at least 200 cells from within 5,6 random
fields in each group. For RAW cell experiments, comparisons
between groups are reported as relative infections rates, where
relative infection rate=# infected cells per 200 cells in
experimental group/infected cells per 200 cells in control group.
For RAW cell experiments, comparisons between groups are
reported as relative infections rates, where relative infection
rate=# infected cells per 200 cells in experimental group/#
infected cells per 200 cells in control group. Since HUVEC are
more permissive for infection and the majority of cells exhibit at
least 1–2 LANA dots (episomes) at MOI,1, we calculated relative
LANA expression for HUVEC experiments as follows: relative
LANA expression=# LANA dots per 200 cells in experimental
group/# LANA dots per 200 cells in control group.
Biochemical assays
1610
4 RAW cells or HUVEC were seeded per well in eight-
well chamber slides and incubated with 10 mM Msg, 0.3 mM Sul
or 0.01–1.0 mM L-NMMA for 12 h at 37uC, then incubated with
cell-free KSHV for 2 h at 37uC. After 12 h, LANA expression
within RAW cells was determined by IFA as outlined above.
Toll-like receptor inhibition
RAW cells were transfected with 1 mg of pcDNA-miRNA or
empty vector control, and after 24 h, incubated with 10 mM of
either drug vehicle or a double-stranded RNA-activated protein
kinase (PKR) inhibitor 2-Aminopurine (InvivoGen, San Diego,
CA) for an additional 3 h. In parallel experiments, transfectants
were incubated with 100 mM of MyD88 inhibitory peptide or
control peptide (Imgenex, San Diego, CA) for an additional 24 h.
Nitrite concentration was quantified within culture supernatants as
detailed previously.
Cell viability assays
Cell viability was assessed using a standard MTT assay as
previously described [70]. A total of 5610
3 RAW cells were
incubated in individual wells in a 96-well plate for 24 h. Serial
dilutions of L-NMMA were then added and after 24–48 h, cells
were incubated in 1 mg/ml of MTT solution (Sigma-Aldrich) at
37uC for 3 h then 50% DMSO overnight and optical density at
570 nm determined by spectrophotometer (Thermo Labsystems).
For assessing cell viability in an environment of oxidative stress, we
transfected or infected RAW cells with pcDNA-miRNA (pcDNA
control) or KSHV (or UV-KSHV control) in the presence of
siRNA targeting xCT or control non-target siRNA. Thereafter,
cells were incubated for 12 h with SNAP and cell viability
determined using 0.4% trypan blue (MP Biomedicals, Solon,
Ohio) to identify dead cells under light microscopy. Relative
differences for cell viability between groups was determined as
follows: relative cell viability=dead cells per 200 cells in
experimental group/dead cells per 200 cells in vehicle control
group.
PCR
Total DNA was isolated using the QIAamp DNA Mini kit
(QIAGEN). Briefly, cells were trypsinized for 59 at 37uC and
collected with 1 mL of ice-cold DMEM. Cells were pelleted at
2,000 rpm for 59, washed, and resuspended in 200 mLo f1 -
phosphate-buffered saline (PBS), and total DNA was prepared
according to the manufacturer’s instructions. Total RNA was
isolated using the RNeasy Mini kit (QIAGEN) as previously
demonstrated [41]. cDNA was synthesized from total RNA using
SuperScript III First-Strand Synthesis SuperMix Kit (Invitrogen)
according to the manufacturer’s instructions. Coding sequences
for genes of interest and b-actin (loading control) were amplified
from 200 ng input cDNA and using iQ SYBR Green Supermix
(Bio-rad). Custom primers sequences used for amplification
experiments (Operon) were as follows: LANA sense 59 TCCCTCTA-
CACTAAACCCAATA 39; LANA antisense 59 TTGCTAATCTCGTT-
GTCCC 39; BACH-1 sense 59 AGGACCTCACGGGCTCTA 39; BACH-
1 antisense 59 ACCCAACCAGGGACACTC 39; xCT sense 59 GGT-
GGAACTGCTCGTAAT 39; xCT antisense 59 CAAAGATCGGGAC-
TGCTA 39; b-actin sense 59 GGGAATGGGTCAGAAGGACT 39; b-
actin antisense 59 TTTGATGTCACGCACGATTT 39. Amplification
experiments were carried out on an iCycler IQ Real-Time PCR
Detection System, and cycle threshold (Ct) values tabulated in
triplicate (DNA) or duplicate (cDNA) for each gene of interest for
each experiment. ‘‘No template’’ (water) controls were also used to
ensure minimal background contamination. Using mean Ct values
tabulated for different experiments and Ct values for b-actin as
loading controls, fold changes for experimental groups relative to
assigned controls were calculated using automated iQ5 2.0
software (Bio-rad). Target amplification for semi-quantitative
PCR (RT-PCR) was performed using a DNA thermal cycler
(Gene Amp PCR System 9700, Applied Biosystems) under
conditions of 94uC for 59, 35 cycles of 94uC for 30 s, 54uC for
30 s, and 72uC for 60 s. Amplicons were subsequently identified
by ethidium bromide-loaded agarose gel electrophoresis.
Immunohistochemistry
Archived, paraffin-embedded KS skin lesions were collected
from the Medical University of South Carolina (MUSC) Hollings
Cancer Center Tumor Bank and the Maize Center for
Dermatopathology (Charleston, S.C.). The diagnosis of KS and
the histopathologic stage of each lesion were verified by an
independent dermatopathologist. Histopathologic staging was
determined using published criteria [71] to characterize lesions
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advanced lesional stage). Tissue sections were deparaffinized and
hydrated through xylene and graded alcohol series, rinsed for 59 in
distilled water, incubated for 109 in 3% hydrogen peroxide, and
following PBS wash, incubated for 309 in a commercial antigen
retrieval solution (Vector Laboratories, Burlingame, CA) at 100uC.
Thereafter, all sections were incubated in 100% rabbit serum for
309 to reduce non-specific staining then for 1 hour with either
control preimmune rabbit sera or xCT antisera diluted 1:400. In
parallel, representative sections were incubated with 1:1200
dilution of the anti-LANA rat monoclonal antibody (ABI). All
sections were subsequently incubated for 309 with a commercially
available biotinylated secondary antibody and reagents according
to the manufacturer’s instructions (Vector Laboratories, Burlin-
game, CA). Bound antibodies were recognized using a 3,39-
Diaminobenzidine (DAB) substrate and nuclei identified using
either hematoxylin to contrast xCT expression, or Methyl Green
to contrast LANA expression. xCT expression was determined for
at least 8 independent tumors representing each of three
histopathologic stages of KS (patches, plaques, and nodules).
LANA expression was determined for patch and nodular lesions in
this cohort.
Statistical analysis
Significance for differences between experimental and control
groups was determined using the two-tailed Student’s t-test (Excel
8.0), and p values ,0.05 or ,0.01 were considered significant or
highly significant, respectively.
Supporting Information
Figure S1 Upregulation of xCT does not increase the total
number of infected HUVEC. (A) HUVEC were incubated with
vehicle (DMSO), Msg or Sul for 12 h followed by purified KSHV
at MOI,0.5–1 for which a fraction (approximately 20%) of
control HUVEC exhibited no LANA expression 16 h later by
IFA. (B) HUVEC were transfected with either control vector or
miRNA-expressing vectors along with an inhibitor of miR-K12-11
or either control non-target siRNA (n) or xCT-specific siRNA
prior to their incubation with KSHV. Relative infection rates were
determined for all groups as previously described. Error bars
represent the S.E.M. for three independent experiments.
Found at: doi:10.1371/journal.ppat.1000742.s001 (0.07 MB TIF)
Figure S2 KSHV miRNAs induce RNS release by macrophages
independent of toll-like receptor pathway activation. (A) RAW
cells were transiently transfected with either control or miRNA-
expressing vectors for 24 h, then incubated with 10 mM 2-
aminopurine (2-AP) or vehicle control for 3 h. (B) In parallel,
RAW cells were transfected as in (A), then incubated with 100 mM
of a control peptide or MyD88 inhibitor peptide for 24 h prior to
nitrite quantification within culture supernatants. Error bars
represent the S.E.M. for three independent experiments.
*=p,0.05.
Found at: doi:10.1371/journal.ppat.1000742.s002 (0.08 MB TIF)
Figure S3 L-NMMA induces no discernable toxicity for RAW
cells. RAW cells were incubated with the indicated concentrations
of L-NMMA and cell viability determined after 48 h by standard
MTT assay according to the manufacturer’s instructions. Error
bars represent the S.E.M. for three independent experiments.
Found at: doi:10.1371/journal.ppat.1000742.s003 (0.09 MB TIF)
Figure S4 Advanced KS lesions contain more KSHV-infected
cells relative to early-stage lesions. Representative early (I) and late
(III) stage lesions were processed for immunohistochemistry as
described in Methods using secondary antibodies alone (control) or
anti-LANA antibodies followed by secondary antibodies (LANA).
LANA expression is indicated by dark brown, punctate intranu-
clear staining seen best at higher power (representative LANA
+
cells are identified with red arrows). Images are shown at original
magnification 620 or 50.
Found at: doi:10.1371/journal.ppat.1000742.s004 (1.60 MB TIF)
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